Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Results may vary significantly, and we undertake no duty to update or revise any forward-looking statements. Please see the press release that we issued today and our quarterly report on Form 10-Q for more information on risks and uncertainties. And now I'd like to turn the call over to Denny. Thank you, Carrie, and good afternoon, everyone, and welcome to our Q3 2025 earnings call. As we get started, let me first welcome Arvind Su to Coherence Oncology, our newly appointed Chief Strategy and Corporate Affairs Officer. Arvind is responsible for investor relations, corporate development, and government affairs. Welcome, Arvind. Thank you. Things are going very well, and today I'm very excited to tell you about the progress we have made on our strategic plan in the last quarter, as well as generally recap our progress for you over the past year as we approach the end of 2025. As you know, we take great pride in our ability to execute, and execution has been strong across the board. For example, you may recall last year me telling you that our objectives included driving the top line, reducing expenses, and strengthening the balance sheet. I'm happy to report we've made great progress across all three. We are particularly pleased by the progress on the balance sheet and expenses, which shows substantial improvement over the past year. My Chief Financial Officer, Brian McMichael, We'll discuss these results with you directly. Now, the Coherence Oncology value proposition for investors is all about our drugs, our evolving data, and the opportunity for deals. We have set ourselves up for success with a sound strategy and have gained significant momentum and hit our stride. Regarding our drugs, Lactorsi is the next generation PD-1. Active in low PD-L1 cancers and approved i...